Stock Research for GALT


Featured Broker: Ally Invest

Get the due diligence for another stock.


GALT Stock Chart & Research Data

The GALT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the GALT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


GALT Due diligence Resources & Stock Charts

The GALT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View GALT Detailed Price Forecast - CNN Money CNN View GALT Detailed Summary - Google Finance
Yahoo View GALT Detailed Summary - Yahoo! Finance Zacks View GALT Stock Research & Analysis -

Stock Analysis

TradeIdeas View GALT Trends & Analysis - Trade-Ideas Barrons View GALT Major Holders - Barrons
NASDAQ View GALT Call Transcripts - NASDAQ Seeking View GALT Breaking News & Analysis - Seeking Alpha
Spotlight View GALT Annual Report - OTC Report View GALT OTC Short Report -
TradeKing View GALT Fundamentals - TradeKing Charts View GALT SEC Filings - Bar Chart
WSJ View Historical Prices for GALT - The WSJ Morningstar View Performance/Total Return for GALT - Morningstar
MarketWatch View the Analyst Estimates for GALT - MarketWatch CNBC View the Earnings History for GALT - CNBC
StockMarketWatch View the GALT Earnings - StockMarketWatch MacroAxis View GALT Buy or Sell Recommendations - MacroAxis
Bullish View the GALT Bullish Patterns - American Bulls Short Pains View GALT Short Pain Metrics -

Social Media Mentions

StockTwits View GALT Stock Mentions - StockTwits PennyStocks View GALT Stock Mentions - PennyStockTweets
Twitter View GALT Stock Mentions - Twitter Invest Hub View GALT Investment Forum News - Investor Hub
Yahoo View GALT Stock Mentions - Yahoo! Message Board Seeking Alpha View GALT Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for GALT - Insider Cow View Insider Transactions for GALT - Insider Cow
CNBC View GALT Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for GALT - OTC Markets
Yahoo View Insider Transactions for GALT - Yahoo! Finance NASDAQ View Institutional Holdings for GALT - NASDAQ

Stock Charts

FinViz View GALT Stock Insight & Charts - StockCharts View GALT Investment Charts -
BarChart View GALT Stock Overview & Charts - BarChart Trading View View GALT User Generated Charts - Trading View

Latest Financial News for GALT

Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology
Posted on Friday March 22, 2019

Providence Cancer Institute and Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, announced today a presentation highlighting the improved response of T cells seen in combination immunotherapy for cancer using GR-MD-02, to be given at a workshop for Recent Advances in Drugging the Innate Immune Response, on Monday, March 25, at 15:00 MDT, at Grays Peak at the Keystone Symposia on Molecular and Cellular Biology in Keystone, Colorado. Elizabeth Sturgill, Ph.D., Postdoctoral Fellow in the laboratory of Associate Member William L. Redmond, Ph.D., at the Earle A. Chiles Research Institute in Portland, Oregon, a division of Providence Cancer Institute, will give an oral presentation entitled “Galectin-3 Inhibition with GR-MD-02 Synergizes with T Cell-Targeting Immunotherapy, Leading to Reduced Immune Suppression and Improved Overall Survival.” The session will focus on the effects GR-MD-02 has had when combined with various T-cell targeting immunotherapies, including both aOX40 and Pembrolizumab (KEYTRUDA®).

Investors Who Bought Galectin Therapeutics Shares Three Years Ago Are Now Up 248%
Posted on Wednesday March 06, 2019

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But if you buy sharesRead More...

Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders
Posted on Wednesday March 06, 2019

As you may know, I have been on the board for slightly over a year and Chairman since May 2018.  While my message relates primarily to the Company’s Rights Offering that was announced today, I also thought it was important to share some of my other thoughts about the Company. Before I speak about anything else, I would like to categorically state that I believe in free market capitalism and its inherent power to improve and save lives.  No other system has proven to possess this ability, and in fact other systems tend to yield the opposite result.  My belief in the power of free market capitalism extends from technical innovation to transparency in most aspects of society.  I intend to cover both aspects as they relate to Galectin Therapeutics.

Galectin Therapeutics Files Registration Statement for Stockholder Rights Offering of Common Stock and Warrants
Posted on Wednesday March 06, 2019

Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, today filed a Registration Statement on Form S-3 with the U.S. Securities and Exchange Commission (“SEC”) (available at with regards to a planned Rights Offering of common stock and warrants to its stockholders. In the Rights Offering the Company will seek to raise between $50 million and $70 million. Richard E. Uihlein, chairman of the board, has indicated his non-binding intent to purchase $20 million in the offering.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.